Measurement of tepotinib by UPLC‒MS/MS and its interaction with naringenin in rats

Abstract We established a method based on ultra performance liquid chromatography tandem mass spectrometry (UPLC‒MS/MS) to quantitatively measure tepotinib, which was validated as acceptable and used in the evaluation of food-drug interactions between tepotinib and naringenin in rats. We used pemiga...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhe Chen, Chaojie Chen, Ya-nan Liu, Xinhao Xu, Shunbin Luo
Format: Article
Language:English
Published: BMC 2024-11-01
Series:BMC Chemistry
Subjects:
Online Access:https://doi.org/10.1186/s13065-024-01293-1
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850062090125967360
author Zhe Chen
Chaojie Chen
Ya-nan Liu
Xinhao Xu
Shunbin Luo
author_facet Zhe Chen
Chaojie Chen
Ya-nan Liu
Xinhao Xu
Shunbin Luo
author_sort Zhe Chen
collection DOAJ
description Abstract We established a method based on ultra performance liquid chromatography tandem mass spectrometry (UPLC‒MS/MS) to quantitatively measure tepotinib, which was validated as acceptable and used in the evaluation of food-drug interactions between tepotinib and naringenin in rats. We used pemigatinib as the internal standard (IS), and acetonitrile and 0.1% formic acid aqueous solution constituted the mobile phase. To extract the target analyte, acetonitrile was used for protein precipitation (PPT). For UPLC‒MS/MS, we performed liquid chromatography using a C18 column, and mass spectrometry was performed in positive multiple reaction monitoring (MRM) mode. Excellent linearity was shown in the range of 0.1–500 ng/mL, and the coefficient of correlation was > 0.99. Notably, the lower limit of quantification (LLOQ) for tepotinib was determined to be 0.1 ng/mL. The intra- and inter-day accuracy of tepotinib ranged from − 1.7 to 7.3%, while the precision was ≤ 8.4%, at three concentrations except LLOQ. The recovery of each substance was ≥ 81.2%, and the matrix effects were within 90.5-98.6%. The stabilities of all analytes under different conditions met all requirements for quantitation in plasma samples. The relevant parameters, such as LLOQ, were evaluated in accordance with the principles of the Food and Drug Administration (FDA) biological verification method. Food-drug interaction study had shown that the plasma concentration of tepotinib could be significantly increased, accompanied by a decrease in clearance rate when administered with 50 mg/kg naringenin. The results showed that naringenin could increase the plasma concentration and decrease the clearance rate of tepotinib when naringenin and tepotinib were administered at the same time.
format Article
id doaj-art-01ac677fb8b84b36ace4047b7ba50bea
institution DOAJ
issn 2661-801X
language English
publishDate 2024-11-01
publisher BMC
record_format Article
series BMC Chemistry
spelling doaj-art-01ac677fb8b84b36ace4047b7ba50bea2025-08-20T02:50:00ZengBMCBMC Chemistry2661-801X2024-11-011811810.1186/s13065-024-01293-1Measurement of tepotinib by UPLC‒MS/MS and its interaction with naringenin in ratsZhe Chen0Chaojie Chen1Ya-nan Liu2Xinhao Xu3Shunbin Luo4The Third Affiliated Hospital of Shanghai University (Wenzhou People’s Hospital)The First Affiliated Hospital of Wenzhou Medical UniversityThe First Affiliated Hospital of Wenzhou Medical UniversityThe First Affiliated Hospital of Wenzhou Medical UniversityThe People’s Hospital of LishuiAbstract We established a method based on ultra performance liquid chromatography tandem mass spectrometry (UPLC‒MS/MS) to quantitatively measure tepotinib, which was validated as acceptable and used in the evaluation of food-drug interactions between tepotinib and naringenin in rats. We used pemigatinib as the internal standard (IS), and acetonitrile and 0.1% formic acid aqueous solution constituted the mobile phase. To extract the target analyte, acetonitrile was used for protein precipitation (PPT). For UPLC‒MS/MS, we performed liquid chromatography using a C18 column, and mass spectrometry was performed in positive multiple reaction monitoring (MRM) mode. Excellent linearity was shown in the range of 0.1–500 ng/mL, and the coefficient of correlation was > 0.99. Notably, the lower limit of quantification (LLOQ) for tepotinib was determined to be 0.1 ng/mL. The intra- and inter-day accuracy of tepotinib ranged from − 1.7 to 7.3%, while the precision was ≤ 8.4%, at three concentrations except LLOQ. The recovery of each substance was ≥ 81.2%, and the matrix effects were within 90.5-98.6%. The stabilities of all analytes under different conditions met all requirements for quantitation in plasma samples. The relevant parameters, such as LLOQ, were evaluated in accordance with the principles of the Food and Drug Administration (FDA) biological verification method. Food-drug interaction study had shown that the plasma concentration of tepotinib could be significantly increased, accompanied by a decrease in clearance rate when administered with 50 mg/kg naringenin. The results showed that naringenin could increase the plasma concentration and decrease the clearance rate of tepotinib when naringenin and tepotinib were administered at the same time.https://doi.org/10.1186/s13065-024-01293-1TepotinibPharmacokineticsNaringeninDrug‒drug interactionUPLC‒MS/MS
spellingShingle Zhe Chen
Chaojie Chen
Ya-nan Liu
Xinhao Xu
Shunbin Luo
Measurement of tepotinib by UPLC‒MS/MS and its interaction with naringenin in rats
BMC Chemistry
Tepotinib
Pharmacokinetics
Naringenin
Drug‒drug interaction
UPLC‒MS/MS
title Measurement of tepotinib by UPLC‒MS/MS and its interaction with naringenin in rats
title_full Measurement of tepotinib by UPLC‒MS/MS and its interaction with naringenin in rats
title_fullStr Measurement of tepotinib by UPLC‒MS/MS and its interaction with naringenin in rats
title_full_unstemmed Measurement of tepotinib by UPLC‒MS/MS and its interaction with naringenin in rats
title_short Measurement of tepotinib by UPLC‒MS/MS and its interaction with naringenin in rats
title_sort measurement of tepotinib by uplc ms ms and its interaction with naringenin in rats
topic Tepotinib
Pharmacokinetics
Naringenin
Drug‒drug interaction
UPLC‒MS/MS
url https://doi.org/10.1186/s13065-024-01293-1
work_keys_str_mv AT zhechen measurementoftepotinibbyuplcmsmsanditsinteractionwithnaringenininrats
AT chaojiechen measurementoftepotinibbyuplcmsmsanditsinteractionwithnaringenininrats
AT yananliu measurementoftepotinibbyuplcmsmsanditsinteractionwithnaringenininrats
AT xinhaoxu measurementoftepotinibbyuplcmsmsanditsinteractionwithnaringenininrats
AT shunbinluo measurementoftepotinibbyuplcmsmsanditsinteractionwithnaringenininrats